GLP-1 RA for Stage 1 Type 1 Diabetes

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Stage 1 Diabetes Mellitus, Type 1

In brief

This study seeks to evaluate the hormone responses of insulin, c-peptide, glucagon, and incretins to semaglutide, a GLP-1 receptor agonist therapy, in individuals with stage 1 type 1 diabetes. The goal of this study is to see if semaglutide can protect beta cell function in this group of people and delay the progression to stage 2 type 1 diabetes.

Key facts

Study ID

NCT07430332

Run by

Children's Hospital Medical Center, Cincinnati

People needed

15

Starts

2027-09-01

Expected to finish

2030-01-01

Last updated by the study team

2026-02-24

Who can join

Age: 12 and older, up to 70. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• Stage 1 Type 1 Diabetes
• Screening OGTT with impaired or loss of first phase insulin secretion but no dysglycemia to suggest stage 2 or stage 3 type 1 diabetes

You may not qualify if…

• History of anaphylaxis or allergies to GLP-1 receptor agonists
• Already on a GLP-1 receptor agonist
• History of bariatric surgery
• Personal or family history of cancer such as medullary thyroid cancer
• Personal history of pancreatitis or pathogenic variants associated with increased risk of pancreatitis
• Severe hypoglycemia within 3 months of study enrollment
• Pregnant, breastfeeding, or the intention of becoming pregnant or not using adequate contraceptive measures
• Adult individuals with BMI < 18.5 kg/m2 and pediatric participants with BMI < 5th percentile

Where it is running

• Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.